Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic Heart Failure

Area of Science:

• Cardiology
• Autonomic Nervous System Research
• Heart Failure Management

Background:

• Novel heart failure (HF) treatments often target baroreflex sensitivity (BRS) and chemoreflex sensitivity (CRS).
• Previous prognostic studies on BRS and CRS in HF were limited and partly predate modern therapies like beta-blockers.

Purpose of the Study:

• To evaluate the clinical and prognostic significance of BRS and CRS in a large cohort of contemporary chronic heart failure patients.
• To determine if BRS and CRS measurements can improve risk stratification in HF management.

Main Methods:

• Assessed BRS (SD method) and CRS (hypoxia/hypercapnia rebreathing) in 425 outpatients with chronic HF (LVEF ≤49%).
• Followed patients for a composite endpoint including cardiac death, ICD shock, or HF hospitalization.
• Patients were on modern HF treatments, with 94% receiving beta-blockers.

Main Results:

• Decreased BRS (36%) was linked to lower exercise tolerance and heart rate variability.
• Increased CRS (20%) correlated with higher norepinephrine and central apneas.
• Both reduced BRS and increased CRS independently predicted adverse outcomes, with combined abnormalities showing the worst prognosis.

Conclusions:

• Abnormal BRS and CRS are prevalent in patients with chronic HF receiving contemporary treatment.
• These autonomic dysfunctions contribute to exercise limitation, ventilation instability, and predict poor outcomes in HF.
• BRS and CRS assessment offers valuable risk stratification for HF patients on modern therapies.